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AbstrACt
Objective Using linked cancer registry and administrative 
data to monitor, tumour, node and metastases (TNM) stage 
and survival from female breast cancer in Australia.
Method Analysis of 2000–2014 diagnoses with 
linked population- based data to investigate: (1) 
sociodemographic predictors of advanced stage (stages 
III and IV), using unadjusted and adjusted logistic 
regression; and (2) sociodemographic factors and stage 
as predictors of breast cancer survival using competing 
risk regression.
Design Population- based registry cohort.
setting and participants 14 759 South Australian women 
diagnosed in 2000–2014.
Primary and secondary outcome measures Stage and 
survival.
results At diagnosis, 46% of women were classified as 
stage I, 39% as stage II, 12% as stage III and 4% as stage 
IV. After adjusting for sociodemographic factors, advanced 
stage was more common: (1) for ages <50 years; and 
although not statistically significant, for ages 80+ years; 
and (2) in women from socioeconomically disadvantaged 
areas. Compared with 2000–2004 diagnoses, stage and 
sociodemographic adjusted risks (sub- HRs (SHRs)) of 
breast cancer death were lower in 2005–2009 (SHR 0.75, 
95% CI 0.67 to 0.83) and 2010–2015 (SHR 0.57, 95% CI 
0.48 to 0.67). Compared with stage I, the SHR was 3.87 
(95% CI 3.32 to 4.53) for stage II, 10.87 (95% CI 9.22 to 
12.81) for stage III, and 41.97 (95% CI 34.78 to 50.65) for 
stage IV. Women aged 70+ years at diagnosis and those 
living in the most socioeconomically disadvantaged areas 
were at elevated risk of breast cancer death, independent 
of stage and sociodemographic factors.
Conclusions Stage varied by age, diagnostic period 
and socioeconomic status, and was a stronger 
predictor of survival than other statistically significant 
sociodemographic predictors. Achieving earlier diagnosis 
outside the original BreastScreen target of 50–69 years 
(as applying <2014) and in residents of socioeconomically 
disadvantaged areas likely would increase cancer survival 
at a population level.
IntrODuCtIOn
Breast cancer is the most common cancer 
recorded in Australian women by popula-
tion registries.1 The 5- year relative survival 
from female breast cancer increased mark-
edly from 72% in 1984–1988 to 91% in 
2011–2015.1 This was attributed mostly 
to treatment advances and earlier cancer 
detection through the national population 
screening programme established in 1991.1 2 
The screening programme offered 2- yearly 
screening mammograms to women in the 
target age of 50–69 years, extending to 74 
years from 2014.1 2 Approximately 54% of 
women in the target age range participate 
during a 2- year period. Women aged 40–49 
years, particularly women with a strong family 
history and those older than the screening 
target, are eligible for screening but not 
actively invited.1 2
Anatomic stage of cancer is a key predictor 
of cancer survival.3 4 The tumour, node and 
strengths and limitations of this study
 ► Shows the utility of readily available registry and ad-
ministrative data for population- based monitoring of 
tumour, node and metastases (TNM) stage.
 ► Shows the face validity of these TNM stage distri-
butions through comparisons with data from special 
studies and international benchmarks.
 ► Shows plausible predictive effects of stage on 
survival.
 ► Study limited to broad TNM categories due to limited 
detail available.
 ► Use of American Joint Committee on Cancer sev-
enth revision with further adaptation required for the 
eighth revision.
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metastases (TNM) staging system is a gold standard for 
staging most solid cancers in clinical practice and can 
be used, with minor modification, to monitor stage at a 
population level through cancer registries.5 TNM stage 
was recorded by population registries for 95% of female 
breast cancers diagnosed in Australia in a one- off study 
in 2011.5 This followed an earlier pathfinder study for 
methodological development.6 Staging data are useful to 
service planners as indicators of need, to assess alignment 
of care with recommendations, to evaluate survival, to 
design interventions to address disparities and to evaluate 
population impact of new therapies by stage.
We use linked registry and administrative data for 
14 759 South Australian women diagnosed with invasive 
breast cancer in 2000–2014 to investigate: (1) sociodemo-
graphic predictors of advanced TNM stage; and (2) TNM 
stage as a predictor of breast cancer survival.
MethODs
study design
Two historic cohort designs were used. The predictor vari-
ables for stage as the outcome in the first analysis were 
sociodemographic characteristics (ie, age at diagnosis, 
country of birth, residential area socioeconomic disad-
vantage and remoteness, and diagnostic period), and for 
survival as the outcome in the second analysis, TNM stage 
and these sociodemographic variables.
Deriving stage
TNM stage was recorded for 96% of women with breast 
cancers diagnosed in 2000–2014, using pathology and 
hospital reporting. The stage distribution was checked 
with aggregated statistical profiles from the Breast Quality 
Audit of Breast Surgeons of Australia and New Zealand.7 
For consistency, staging processes followed national 
guidelines developed for population- based registries and 
used in a 2011 national study.5 6
Breast tumour diameters and nodal status were obtained 
for assessing stage through the South Australian Cancer 
Registry (SACR) and distant metastases were indicated 
by inpatient diagnosis codes. SA Clinical Cancer Registry 
data for major public hospitals were used for validity 
checking and to fill gaps. Receptor status and other 
biomarkers were not addressed as they were not routinely 
recorded by registries throughout the study period and 
not included in the national TNM staging protocol devel-
oped for population- wide monitoring.5
Stage was broadly classified as stage I, II, III or IV, 
according to criteria of the American Joint Committee on 
Cancer (AJCC, seventh revision), to reduce inconsisten-
cies from changes in AJCC revisions.8
Data sources
Population- based invasive breast cancer data (Interna-
tional Classification of Diseases (ICD)- O-3 C50) were 
obtained from the SACR. Operations of the SACR have 
been described previously.9 All invasive breast cancers 
diagnosed in South Australia were included and coded 
using international registry standards.9 10 Reporting 
by pathology laboratories and hospitals is a legal 
requirement.9
For each cancer, SACR records the primary site, 
morphology, diagnosis date and the woman’s country of 
birth, death date and cause, and postcode- derived relative 
socioeconomic disadvantage and geographical remote-
ness.9 The Registry of Births, Deaths and Marriages and 
National Death Index are used as sources of death data, 
with causes coded to cancer type or non- cancer.9
Linkage of SACR and hospital inpatient data was 
predominantly through South Australia Northern Terri-
tory DataLink using name, sex, date of birth and address for 
matching.11 12 Patient identifiers were separated from clin-
ical content to protect privacy.12 The process comprised: 
(1) after record deduplication, deterministic matching to 
a Master Linkage File built from extracts of over 60 data 
sources, achieving 97% deterministic matching of inpa-
tient and SACR data; (2) non- exact matches then linked 
through probabilistic means; (3) uncertain matches cler-
ically reviewed for final determination.
Other variables
Age at diagnosis was classified as: <50, 50–59, 60–69, 70–79 
or 80+ years; and country of birth as Australia, other 
predominantly English- speaking country or predomi-
nantly non- English speaking country, as previously.13 14 
Socioeconomic status was derived from residential post-
code at diagnosis using the Socioeconomic Index for 
Areas (SEIFA) Index of Relative Socioeconomic Disad-
vantage expressed in quintiles.15 Residential area was 
classified as a major city, inner regional, outer regional, 
remote or very remote area, using the Australian Stan-
dard Geographical Classification Remoteness Index.16 
Diagnostic period was categorised as 2000–2004, 2005–
2009 and 2010–2014.
statistical analysis
TNM stage was analysed by population characteristic 
using analysis of variance for age and conventional χ2 
or ranked tests depending on variable distributions.17 18 
Advanced stage (III or IV) as opposed to early stage (I or 
II) was analysed by sociodemographic descriptors using 
unadjusted and adjusted logistic regression.17 18
Deaths were classified as due to breast cancer, as 
compared with another cause, and predictors of survival 
from breast cancer were analysed for period from diag-
nosis to death or until 31 December 2014, whichever 
came first. Predictors of breast cancer death were inves-
tigated using competing risk regression models (Stata 
module ‘stcrreg’),18 19 regarding deaths from causes other 
than breast cancer as the competing risk. Predictors were 
adjusted for stage and sociodemographic characteristics.
Stata V.14 (StataCorp) was used, with statistical signif-
icance set at p<0.05. All survival analyses used complete 
case data.
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(n=14 759) P value
Mean age (year) (SD) 61.0 (12.2) 60.0 (13.9) 59.0 (14.3) 65.3 (15.2) 60.6 (13.3) <0.001
Age group <0.001
  <50 1143 (17.0%) 1436 (24.9%) 486 (28.5%) 101 (18.2%) 3166 (21.5%)
  50–59 1877 (27.9%) 1493 (25.8%) 429 (25.1%) 103 (18.5%) 3902 (26.4%)
  60–69 2121 (31.6%) 1344 (23.3%) 363 (21.3%) 112 (20.1%) 3940 (26.7%)
  70–79 1072 (16.0%) 929 (16.1%) 267 (15.6%) 124 (22.3%) 2392 (16.2%)
  80+ 505 (7.5%) 575 (10.0%) 163 (9.5%) 116 (20.9%) 1359 (9.2%)
Country of birth 0.002
  Australia 4101 (61.0%) 3450 (59.7%) 1035 (60.6%) 332 (59.7%) 8918 (60.4%)
  Other English- speaking countries 985 (14.7%) 858 (14.9%) 226 (13.2%) 75 (13.5%) 2144 (14.5%)
  Non- English- speaking countries 700 (10.4%) 715 (12.4%) 211 (12.4%) 69 (12.4%) 1695 (11.5%)
  Unknown 932 (13.9%) 745 (13.1%) 236 (13.8%) 80 (14.4%) 2002 (13.6%)
SEIFA IRSD quintile <0.001
  1 (most disadvantaged) 1057 (15.7%) 1063 (18.4%) 319 (18.7%) 131 (23.6%) 2570 (17.4%)
  2 1404 (20.9%) 1126 (19.5%) 332 (19.4%) 125 (22.5%) 2987 (20.2%)
  3 1342 (20.0%) 1165 (20.2%) 355 (20.8%) 112 (20.1%) 2974 (20.2%)
  4 1342 (20.0%) 1168 (20.2%) 341 (20.0%) 88 (15.8%) 2939 (19.9%)
  5 (least disadvantaged) 1572 (23.4%) 1254 (21.7%) 361 (21.1%) 100 (18.0%) 3287 (22.3%)
Remoteness 0.310
  Major city 4978 (74.1%) 4293 (74.3%) 1290 (75.5%) 418 (75.2%) 10 979 (74.4%)
  Inner regional 760 (11.3%) 651 (11.3%) 186 (10.9%) 57 (10.3%) 1654 (11.2%)
  Outer regional 783 (11.7%) 653 (11.3%) 193 (11.3%) 64 (11.5%) 1693 (11.5%)
  Remote 162 (2.4%) 141 (2.4%) 32 (1.9%) 13 (2.3%) 348 (2.4%)
  Very remote 34 (0.5%) 39 (0.7%) 7 (0.4%) 4 (0.7%) 84 (0.6%)
  Unknown 1 (0.01%) 0 0 0 1 (0.01%)
Diagnosis period 0.346
  2000–2004 2022 (30.1%) 1889 (32.7%) 452 (26.5%) 197 (35.4%) 4560 (30.9%)
  2005–2009 2368 (35.3%) 1881 (32.6%) 630 (36.9%) 223 (40.1%) 5102 (34.6%)
  2010–2014 2328 (34.7%) 2007 (34.7%) 626 (36.7%) 136 (24.5%) 5097 (34.5%)
Vital status <0.001
  Died 720 (10.7%) 1186 (20.5%) 582 (34.1%) 436 (78.4%) 2924 (19.8%)
  Alive 5998 (89.3%) 4591 (79.4%) 1126 (65.9%) 120 (21.6%) 11 835 (80.2%)
Cause of death <0.001
  Breast cancer 209 (29.0%) 680 (57.3%) 460 (79.0%) 391 (89.7%) 1740 (59.5%)
  Other cancers 170 (23.6%) 136 (11.5%) 42 (7.2%) 19 (4.4%) 367 (12.6%)
  Non- cancer 341 (47.6%) 370 (31.2%) 80 (13.8%) 26 (6.0%) 817 (27.9%)
Vital status and cause of death from cancer registry, censoring on 31 December 2014.
*P value from one- way analysis of variance for age in years and χ2 or ranked tests for others (see the Methods section).
IRSD, Index of Relative Socioeconomic Disadvantage; SEIFA, Socioeconomic Index for Areas.
Patient and public involvement
Patients and/or the public were not involved in the 




The mean age of the 14 759 staged cases was 61 years, with 
53% aged 50–69 years (table 1). For women of known 
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Table 2 ORs (95% CIs) for diagnosis with advanced (tumour, node and metastases (TNM) III or IV) as opposed to more 




OR for advanced 
stage (unadjusted)
OR for advanced 
stage* (adjusted)
Age at diagnosis (years)
  <50 587/3166 1.00 1.00
  50–59 532/3902 0.69 (0.61 to 0.79) 0.70 (0.62 to 0.80)
  60–69 475/3940 0.60 (0.53 to 0.69) 0.60 (0.53 to 0.69)
  70–79 391/2392 0.86 (0.75 to 0.99) 0.85 (0.74 to 0.98)
  80+ 279/1359 1.13 (0.98 to 1.33) 1.11 (0.95 to 1.31)
Country of birth
  Australia 1370/8918 1.00 1.00
  Other English- speaking countries 301/2144 0.90 (0.79 to 1.03) 0.91 (0.80 to 1.04)
  Non- English- speaking countries 280/1695 1.09 (0.95 to 1.26) 1.08 (0.93 to 1.24)
  Unknown 316/2002 1.04 (0.91 to 1.18) 1.02 (0.89 to 1.16)
Diagnostic period
  2000–2004 649/4560 1.00 1.00
  2005–2009 853/5102 1.21 (1.08 to 1.35) 1.20 (1.07 to 1.34)
  2010–2014 762/5097 1.06 (0.95 to 1.19) 1.06 (0.95 to 1.19)
Residential remoteness
  Major city 1078/10 979 1.00 1.0
  Inner regional 243/1654 0.93 (0.81 to 1.08) 0.96 (0.82 to 1.11)
  Outer region/remote/very remote 313/2126 0.94 (0.82 to 1.07) 0.88 (0.77 to 1.02)
SEIFA IRSD quintile
  1 (most disadvantaged) 450/2570 1.00 1.00
  2 457/2987 0.85 (0.74 to 0.98) 0.87 (0.75 to 1.00)
  3 467/2974 0.88 (0.76 to 1.01) 0.88 (0.76 to 1.01)
  4 429/2939 0.81 (0.70 to 0.93) 0.79 (0.68 to 0.92)
  5 (least disadvantaged) 461/3287 0.77 (0.67 to 0.89) 0.75 (0.65 to 0.87)
*Adjusted ORs from logistic regression model including age, country of birth, diagnosis period, SES quintile and residential remoteness.
IRSD, Index of Relative Socioeconomic Disadvantage; SEIFA, Socioeconomic Index for Areas.
country of birth, 70% were born in Australia, 17% in 
other predominantly English- speaking countries and 13% 
in predominantly non- English- speaking countries. SACR 
data indicated that 30% of the cohort were born outside of 
Australia. Of these, 50% were born in the UK/Ireland, 21% 
in Southern or Eastern Europe, 11% in Western Europe, 
9% in Asia and 9% elsewhere. Almost three quarters (74%) 
resided in a major city, 11% in inner regional locations 
and 14% in outer regional, remote or very remote areas. 
The percentage by residential socioeconomic disadvantage 
ranged from 17% for the most disadvantaged to 22% for 
the least disadvantaged quintile. The percentage by diag-
nostic period increased from 31% for 2000–2004 to 35% 
for 2005–2009 and 2010–2014.
Cancer stage
The TNM stage distribution was: stage I, 46%; stage II, 
39%; stage III, 12%; and stage IV, 4%. Differences in 
stage were found in unadjusted analysis by age (p<0.001), 
country of birth (p=0.002) and SEIFA disadvantage 
(p<0.001), but not by residential remoteness (p=0.310) 
or diagnostic period (p=0.346; table 1).
Compared with women aged <50 years at diagnosis, the 
adjusted OR for advanced stage was: 0.70 (95% CI 0.62 
to 0.80) for ages 50–59 years, 0.60 (95% CI 0.53 to 0.69) 
for 60–69 years and 0.85 (95% CI 0.74 to 0.98) for 70–79 
years. Higher adjusted risks of advanced stage tended 
occur in ages <50 years and 80+ years, although the differ-
ence for ages 80+ years compared with <50 years did not 
achieve statistical significance (OR 1.11, 95% CI 0.95 to 
1.31; table 2).
Adjusted ORs for advanced cancer were lower among 
women of least residential socioeconomic disadvantage 
(Q4/Q5) than most disadvantage (Q1; OR 0.79 95% CI 
0.68 to 0.92) for Q4 and OR 0.75 (95% CI 0.65 to 0.87) 
for Q5 (least disadvantage). Risk of advanced stage did 
5Li M, et al. BMJ Open 2020;10:e037069. doi:10.1136/bmjopen-2020-037069
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not differ in adjusted analyses by country of birth or resi-
dential remoteness (table 2).
While the adjusted OR for advanced cancer was 
higher in 2005–2009 than the 2000–2004 baseline (OR 
1.20, 95% CI 1.07 to 1.34), the difference between 
2010–2014 and 2000–2004 was not significant (OR 1.06 
95% CI 0.95 to 1.19).
Analyses by age showed heterogeneity for advanced stage 
by diagnostic period. During 2000–2004, women aged 80+ 
years were significantly more likely to have advanced stage 
than the reference age (<50 years; OR 1.50 95% CI 1.12 to 
2.01) but significant corresponding associations were not 
observed in 2005–2009 (OR 1.16, 95% CI 0.90 to 1.50) or 
2010–2014 (OR 0.82, 95% CI 0.62 to 1.10).
Supplementary analysis
When the analysis was repeated subclassifying age <50 years 
as <40 and 40–49 years, adjusted ORs for advanced stage 
were essentially unchanged for sociodemographic factors. 
Compared with <40 years, the adjusted ORs were: 0.79 
(0.64 to 0.97) for 40–49 years; 0.59 (0.48 to 0.72) for 50–59 
years; 0.50 (0.41 to 0.62) for 60–69 years; 0.71 (0.58 to 0.88) 
for 70–79 years; and 0.93 (0.75 to 1.16) for 80+ years.
breast cancer mortality
Of the 14 759 women, 2924 (19.8%) had died from any 
cause and 1740 (11.8%) from breast cancer by the end 
of the study (table 1). Adjusted sub- HRs (SHRs; table 3) 
varied by: (1) stage—increasing with more advanced stage 
to 41.97 (95% CI 34.78 to 50.65) for stage IV compared 
with stage 1; (2) age at diagnosis—increasing with age to 
2.24 (95% CI 1.88 to 2.66) for age 80+ compared with 
<50 years; and (3) residential socioeconomic disadvan-
tage—reducing to 0.73 (95% CI 0.62 to 0.87) for the least 
compared with most disadvantaged quintile. The adjusted 
risk of breast cancer death reduced, independently of 
stage and sociodemographic factors, in the later diag-
nostic periods compared with the 2000–2004 reference 
(SHR 0.75, 95% CI 0.67 to 0.83) for 2005–2009 and 0.57 
(95% CI 0.48 to 0.67) for 2010–2014. Significant differ-
ences were not found in unadjusted or adjusted analyses 
by country of birth or residential remoteness.
Supplementary analysis
When the analysis was repeated subclassifying age <50 
years as <40 and 40–49 years, adjusted SHRs were essen-
tially the same as in the earlier analysis by other sociode-
mographic factors and stage. Compared with <40 years, 
the adjusted SHRs were: 0.64 (0.52 to 0.80) for 40–49 
years; 0.80 (0.65 to 0.97) for 50–59 years; 0.77 (0.62 to 
0.94) for 60–69 years; 1.04 (0.84 to 1.28) for 70–79 years; 
and 1.63 (1.30 to 2.03) for 80+ years.
DIsCussIOn
A very similar stage distribution was found for staged 
invasive female breast cancers in South Australia in 2000–
2014 to that for the Australian national study for 2011.5 
This may reflect the common standards for screening, 
treatment and accreditation, and similar although not 
identical screening participation.20–22
Stage distributions were also similar in South Australia 
to distributions for staged breast cancers in Canada and 
England.5 The distributions in South Australia (2000–
2014) compared with Australia (2011), Canada (2013) 
and England (2012) were: (1) stage I—46% compared 
with 46%, 47% and 44% respectively; (2) stage II—39% 
compared with 37%, 35% and 39%, respectively; (3) stage 
III—12% compared with 13%, 12% and 10%, respec-
tively; and (4) stage IV—4% compared with 5%, 6% and 
7%, respectively5 (figure 1).
These differences appear minor and smaller than antic-
ipated, given potential effects of methodological and 
geographic differences.5 The marginally higher propor-
tion of early stage I and II of 85% for South Australia 
compared with 82% for Australia may also have been 
influenced by a marginally higher screening participation 
in South Australia.20 21
The proportion with advanced cancers (stage III or 
IV) was lower for ages 50–79 years than younger or older 
women. A similar pattern was seen for staged cancers in 
Australia (2011) where the age- standardised percentage 
with stages III or IV was 16% compared with 21% for 
younger and 25% for older women.5 This likely reflects 
targeting of women aged 50–69 years for screening in 
2000–2013 and availability of screening on demand from 
70 years during the study period.1 2 In addition, women 
aged 80+ years, through a higher prevalence of frailty 
and comorbidity, may have been slower to access clin-
ical services.5 Notably, a higher OR for advanced cancers 
presented in ages 80+ years than in younger women in 
2000–2014, although this was less obvious for later diag-
nostic periods, especially 2010–2014, potentially reflecting 
a growing emphasis on early diagnosis in older women.22 
Supplementary analysis showed a lower OR for advanced 
cancer in women aged 40–49 than <40 years and in the 
50–79 year age range, likely reflecting screening avail-
ability and potentially biological factors.1 2
Among women with breast cancer, the proportion by 
age ranged from 17% for the most disadvantaged quin-
tile to 22% for the least disadvantaged, consistent with 
the Australia- wide gradient for 2010–2014.5 Residents of 
the most disadvantaged quintile were at higher risk of 
advanced cancers than the least disadvantaged quintile in 
this study, which is confirmatory of the difference found 
nationally in 2011 (21% vs 16%).5 Screening participation 
could have contributed, it being lower for disadvantaged 
than advantaged areas.5 Although screening services have 
introduced initiatives to address needs of women from 
disadvantaged areas, more research into barriers and 
opportunities would be desirable.
The absence of differences in risk of advanced stages in 
our study by residential remoteness may reflect the reach 
of mobile screening clinics in rural areas. Differences 
also appeared small in the national survey with 18% of 
staged cases having advanced cancers among major city 
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Table 3 Sub- HRs (SHRs; 95% CIs) for breast cancer- specific mortality in South Australia for invasive breast cancers 
diagnosed in 2000–2014 (n=14 759)
Characteristic Breast cancer death/death Unadjusted SHR* Adjusted SHR†
TNM stage
  I 209/720 1.00 1.00
  II 680/1186 3.99 (3.42 to 4.65) 3.87 (3.32 to 4.53)
  II 460/582 10.69 (9.09 to 12.57) 10.87 (9.22 to 12.81)
  IV 391/436 45.82 (38.15 to 55.03) 41.97 (34.78 to 50.65)
Age at diagnosis (years)
  <50 365/405 1.00 1.00
  50–59 404/526 0.83 (0.77 to 1.02) 1.10 (0.95 to 1.27)
  60–69 342/556 0.78 (0.68 to 0.90) 1.05 (0.91 to 1.22)
  70–79 329/699 1.31 (1.13 to 1.52) 1.43 (1.22 to 1.67)
  80+ 300/738 2.22 (1.89 to 2.59) 2.24 (1.90 to 2.66)
Country of birth
  Australia 1049/1777 1.00 1.00
  Other English- speaking countries 247/412 0.98 (0.85 to 1.12) 1.01 (0.87 to 1.17)
  Non- English- speaking countries 200/346 1.02 (0.87 to 1.18) 0.98 (0.84 to 1.15)
  Unknown 244/389 1.08 (0.94 to 1.25) 1.15 (1.00 to 1.33)
Diagnostic period
  2000–2004 884/1512 1.00 1.00
  2005–2009 654/1076 0.81 (0.73 to 0.90) 0.75 (0.67 to 0.83)
  2010–2014 202/336 0.62 (0.53 to 0.72) 0.57 (0.48 to 0.67)
Residential remoteness
  Major city 1302/2186 1.00 1.00
  Inner regional 185/313 0.99 (0.85 to 1.16) 1.01 (0.86 to 1.20)
  Outer regional/remote/very remote 253/425 1.01 (0.88 to 1.15) 0.97 (0.84 to 1.13)
SEIFA IRSD quintile
  1 (most disadvantaged) 364/605 1.00 1.00
  2 371/604 0.88 (0.76 to 1.02) 0.93 (0.79 to 1.09)
  3 353/613 0.80 (0.69 to 0.93) 0.85 (0.72 to 0.99)
  4 328/544 0.79 (0.68 to 0.92) 0.85 (0.73 to 1.00)
  5 (least disadvantage) 324/558 0.67 (0.58 to 0.78) 0.73 (0.62 to 0.87)
*Unadjusted SHRs derived from univariate competing risk regression modelling, deaths followed to 31 December 2014.
†Adjusted SHRs derived from multivariate competing risk regression model adjusting by including cancer stage, age, country of birth, 
diagnosis period, residential remoteness and Socioeconomic Index for Areas (SEIFA) quintile.
IRSD, Index of Relative Socioeconomic Disadvantage.
residents compared with 17% for regional areas and 20% 
for remote and very remote areas.5 The absence of a 
difference in risk by country of birth in the present study 
is reassuring from an equity perspective.
Predictably the proportion of cases dying from breast 
cancer increased with TNM stage (from 3% for stage I to 
70% for stage IV). Adjusted analyses confirmed stage to be 
the strongest predictor of survival. The National Breast-
Screen Evaluation Report of 2009, using data sourced 
from the Victorian Cancer Registry, indicated that the 
percentage of breast cancers with diameters ≤15 mm was 
higher at 64% in women notified through BreastScreen 
than the 39% for other women in the 50–69 year age range, 
which likely contributed to the BreastScreen- related 
survival advantage.23 An Expert Panel from 16 countries 
assembled by the International Agency for Research on 
Cancer reported in 2015 that participation of women 
aged 50–69 years in mammography screening can reduce 
the risk of breast cancer death by approximately 40%.24 
In addition, the national study showed a 5- year relative 
survival of 91% for 2011–2015 for all stages combined, 
but varying markedly by stage (ie, >95% of women with 
stages TNM I and II survived 5 years compared with 81% 
for stage III and 32% for stage IV).5
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Figure 1 % of breast cancer survival by cancer stage in South Australia (SA) comparing with other countries during 2000–
2014. Data source: Cancer Australia.5
Older age at diagnosis was predictive of lower survival 
in the present study, with the lowest survival applying to 
ages 80+ years. The national study provided consistent 
findings with the lowest 5- year relative survival of 81% 
applying to women aged 75+ years.5 Supplementary anal-
ysis with a finer age breakdown confirmed the lowest 
survival to apply to 80+ ages in the present study.
Socioeconomic status was also predictive with residents 
of the least disadvantaged areas having the highest survival. 
This is consistent with national data for 2006–2010.5 Factors 
potentially responsible warrant further study and could 
include artificial effects of lead time and overdiagnosis, plus 
real effects due to differences in health literacy, variations 
in engagement with health protection, competing pres-
sures on time and resources by level of disadvantage, and 
a tendency for lower screening participation in the most 
disadvantaged areas.5
A major increase in survival outcomes was evident in 
more recent diagnostic periods, which is also seen in the 
national data where 5- year relative survival increased from 
72% in 1984–1988 to 91% in 2010–2014.5 This may reflect 
combination effects of artificial influences from differ-
ences in lead time and overdiagnosis, plus real benefits 
from screening and treatment advances, among them 
an increased use of specialised breast cancer centres and 
advances in adjuvant therapies.24 The more advanced 
breast cancer stage distribution for South Australia in 
2005–2009 was unexpected and warrants further inves-
tigation. These years represented the end of the film- 
reading era prior to transfer to digital technology. Despite 
this peak in advanced cases, it is reassuring to see a steady 
secular increase in survival.
The present study follows the national study of stage.5 
Stage was derived from pathology reporting and hospital 
reporting and stage distributions were checked with statis-
tical profiles from the Quality Audit of Breast Surgeons of 
Australia and New Zealand.7 Results complement earlier 
data: from New South Wales, Australia, based on local-
ised, regional and distant Surveillence, Epidemiology, 
and End Results program (SEER) Summary Stage, where 
a similar survival gradient was observed with higher stage 
for follow- up limited to <3 years from diagnosis25 26; and 
on breast cancer mortality trends for Australia which did 
not include data on stage or survival.27
Limitations included restricting stage to four major 
categories to avoid inconsistencies due to changes at 
a more detailed level across versions of AJCC TNM 
coding. Further efforts are needed to improve accuracy 
of staging, although the 96% coverage of invasive cancers 
with staging was high and similar to coverage observed in 
other studies in Australia, Canada and England.5 Another 
limitation was lack of adjustment for postdiagnostic 
explanatory variables such as treatment practices, which 
may have affected sociodemographic survival differences. 
We plan to address these aspects in a further investigation 
of linked data.
Data on race and ancestry were not available for this 
study. While Indigenous status is recorded, numbers 
were too small for meaningful analysis. We therefore 
used country of birth as a crude marker of diversity 
according to whether predominantly English speaking. It 
is important with increasing ethnic diversity in Australia 
that greater attention be given to ethnic descriptors in 
health data collections.
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COnClusIOns
Stage was a stronger predictor of survival outcome than 
sociodemographic predictors. Achieving earlier diagnosis 
outside the original screening target of 50–69 years and in 
residents of socioeconomically disadvantaged areas likely 
would further increase cancer survival at a population 
level. The present data show plausible stage distributions 
and effects on survival, using readily available data for 
staging. The uptake of voluntary screening from age of 40 
years may improve outcomes for patients under 50 years 
and more targeted screening for patients with genetic risk 
and breast density may have positive impacts.
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